Table 1

Stages of the scoping reviews

1. Research question identified1.1. Overarching goalTo explore the depth and breadth of evidence for the indications, epidemiology, genetics, efficacy and safety of drugs that act on JAK/STAT pathway in the treatment of patients with dermatological diseases.
1.2. Research questionWhat are the indications, epidemiology, genetics, efficacy and safety of drugs that act on JAK/STAT pathway in the treatment of dermatological diseases?
1.3. Purposes of this scoping review1.3.1. Review the evidence of indications for drugs that act on JAK/STAT pathway in the treatment of dermatogical diseases.
1.3.2. Review the evidence of epidemiology of drugs acting on JAK/STAT pathway in the treatment of dermatogical diseases.
1.3.3. Review the evidence of genetics of drugs acting on JAK/STAT pathway in the treatment of dermatogical diseases.
1.3.4. Review the evidence on efficacy of the drugs that act on JAK/STAT pathway in the treatment of dermatogical diseases.
1.3.5. Review the evidence on safety of drugs that act on JAK/STAT pathway in the treatment of dermatogical diseases.
1.3.6. Obtain concrete research questions that can be answered through a systematic review.
1.3.7. Identify research gaps in the existing literature.
2. Identifying relevant literature2.1. We will perform a three-step search2.1.1. First search: an initial limited search of the MEDLINE and EMBASE databases to find keywords in the title, abstract and the index terms used to describe the articles.
2.1.2. Second search: a search of MEDLINE and EMBASE using all identified keywords. Additionally, CINAHL, Scopus and Web of Science to the search engines will be searched in this second step.
2.1.3. Third search: the reference lists of all identified reports and articles will be searched for additional studies.
2.2. We will include the studies published in full text in English until October 2018.
2.3. We will contact authors, of primary studies or reviews, for further information, if this is relevant.
2.4. The search and selection will be done by at least two reviewers and in case of disagreement will be decided by agreement with a third reviewer.
3. Selecting studies3.1. Inclusion criteria3.1.1. We will include in the review the studies on the human use of drugs inhibitors of JAK/STAT pathway published on the topics: indications, epidemiology, genetics, efficacy and safety.
3.1.2. Design of the studies: we will include guidelines, systematic reviews, randomised clinical trials, observational studies, cross sectional case report and series.
3.2. Exclusion criteria3.2.1. We will exclude narrative reviews and studies performed in vitro or using animal models.
4. Charting the data4.1. We will extract the data in a predefined form.
4.2. From each study we will extract title, objective, main variables related to patients, intervention, comparator, outcomes (efficacy and safety) and bibliographic data.
4.3. We will classify the studies by treatment indication.
4.4. The list of studies, variables and data of there view will be published in an online file.
4.5. The data collection will be done by at least two reviewers and in case of disagreement will be decided by agreement with a third reviewer.
5. Collating, summarising and reporting results5.1. The results of comprehensive search will be presented using the PRISMA flow diagram.
5.2. We will synthesise qualitatively the evidence obtained ordering it by topics: indications, mechanism of action, efficacy and safety of drugs that act on JAK/STAT pathway to treat dermatological diseases and we will present it in a diagrammatic tabular form and in a descriptive format.
5.3. We will use the extension of PRISMA for scoping review for the notification of the review.
6. Differences between the protocol and the overviewAny changes in the methodology that need to be carried out throughout the study will be detailed together with the results publication.
  • JAK/STAT, Janus kinase and Signal Transducer and Activator of Transcription  protein; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.